Microbiota and Bone Health: The Gut-Musculoskeletal Axis

Rizzoli, René

doi:10.1007/s00223-018-0391-7

Cited by 9 publications

(8 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2021, 22, 8980 2 of 20 by physical inactivity and by a low-fiber diet rich in sugar and saturated fats. All these different factors are associated with an alteration of composition and function of the gut microbiota, causative of low-grade inflammation, which is an important contributor to joint damage in OA [3,4]. This microbial dysbiosis could represent the missing link between the different conditions contributing to OA pathogenesis, suggesting microbiota as a new pharmacological strategy for OA management [5,6].…”

Section: Introductionmentioning

confidence: 99%

A Combination of Celecoxib and Glucosamine Sulfate Has Anti-Inflammatory and Chondroprotective Effects: Results from an In Vitro Study on Human Osteoarthritic Chondrocytes

Cheleschi

Tenti

Giannotti

et al. 2021

IJMS

View full text Add to dashboard Cite

This study investigated the possible anti-inflammatory and chondroprotective effects of a combination of celecoxib and prescription-grade glucosamine sulfate (GS) in human osteoarthritic (OA) chondrocytes and their possible mechanism of action. Chondrocytes were treated with celecoxib (1.85 µM) and GS (9 µM), alone or in combination with IL-1β (10 ng/mL) and a specific nuclear factor (NF)-κB inhibitor (BAY-11-7082, 1 µM). Gene expression and release of some pro-inflammatory mediators, metalloproteinases (MMPs), and type II collagen (Col2a1) were evaluated by qRT-PCR and ELISA; apoptosis and mitochondrial superoxide anion production were assessed by cytometry; B-cell lymphoma (BCL)2, antioxidant enzymes, and p50 and p65 NF-κB subunits were analyzed by qRT-PCR. Celecoxib and GS alone or co-incubated with IL-1β significantly reduced expression and release of cyclooxygenase (COX)-2, prostaglandin (PG)E2, IL-1β, IL-6, tumor necrosis factor (TNF)-α, and MMPs, while it increased Col2a1, compared to baseline or IL-1β. Both drugs reduced apoptosis and superoxide production; reduced the expression of superoxide dismutase, catalase, and nuclear factor erythroid; increased BCL2; and limited p50 and p65. Celecoxib and GS combination demonstrated an increased inhibitory effect on IL-1β than that observed by each single treatment. Drugs effects were potentiated by pre-incubation with BAY-11-7082. Our results demonstrated the synergistic effect of celecoxib and GS on OA chondrocyte metabolism, apoptosis, and oxidative stress through the modulation of the NF-κB pathway, supporting their combined use for the treatment of OA.

show abstract

Section: Introductionmentioning

confidence: 99%

A Combination of Celecoxib and Glucosamine Sulfate Has Anti-Inflammatory and Chondroprotective Effects: Results from an In Vitro Study on Human Osteoarthritic Chondrocytes

Cheleschi

Tenti

Giannotti

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…On the one hand, the gut microbiota shows variability depending on several conditions, such age, sex, diet, environmental conditions, and diseases [ 26 , 27 ]. On the other hand, bone is also a dynamic organ undergoing constant remodeling, maintaining bone mass and calcium serum level homeostasis [ 26 ].…”

Section: The Gut-bone Axismentioning

confidence: 99%

Role of Dietary Supplements and Probiotics in Modulating Microbiota and Bone Health: The Gut-Bone Axis

Sire

Sire²,

Curci

et al. 2022

Cells

View full text Add to dashboard Cite

Osteoporosis is characterized by an alteration of bone microstructure with a decreased bone mineral density, leading to the incidence of fragility fractures. Around 200 million people are affected by osteoporosis, representing a major health burden worldwide. Several factors are involved in the pathogenesis of osteoporosis. Today, altered intestinal homeostasis is being investigated as a potential additional risk factor for reduced bone health and, therefore, as a novel potential therapeutic target. The intestinal microflora influences osteoclasts’ activity by regulating the serum levels of IGF-1, while also acting on the intestinal absorption of calcium. It is therefore not surprising that gut dysbiosis impacts bone health. Microbiota alterations affect the OPG/RANKL pathway in osteoclasts, and are correlated with reduced bone strength and quality. In this context, it has been hypothesized that dietary supplements, prebiotics, and probiotics contribute to the intestinal microecological balance that is important for bone health. The aim of the present comprehensive review is to describe the state of the art on the role of dietary supplements and probiotics as therapeutic agents for bone health regulation and osteoporosis, through gut microbiota modulation.

show abstract

“… 55 Several dietary nutrients including calcium are digested and released by intestinal bacteria, while microbiota manipulation with prebiotics (for a detailed description see section ‘Intervention studies with prebiotics’ and Table 1 ) improves calcium bioavailability through several possible mechanisms. 12 First, the transformation of prebiotics to SCFAs lowers the pH in the intestinal lumen; such changes are alleged to hinder the formation of calcium–phytate/oxalate complexes, thereby increasing the amount of available calcium for absorption. Second, the ingestion of prebiotics has been associated with increases in cell density, intestinal crypt depth, and blood flow, which may increase intestinal surface area and enhance calcium absorption.…”

Section: Interactions Between the Microbiome And Treatments For Muscumentioning

confidence: 99%

“… 10 The microbiome is dynamic throughout the lifespan and varies greatly within and between individuals as a result of intrinsic and extrinsic factors. 10 – 12 Most microbes live symbiotically with the human host and promote health through their involvement in a vast array of functions ranging from maintaining intestinal barrier function and nutrient fermentation to endocrine and immune functions. Conversely, perturbations in microbiota composition, functional and metabolic capacity, collectively termed dysbiosis, have been associated with intestinal and extra-intestinal disorders including musculoskeletal diseases.…”

Section: Introductionmentioning

confidence: 99%

Interactions of the microbiome with pharmacological and non-pharmacological approaches for the management of ageing-related musculoskeletal diseases

Papageorgiou

2021

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Despite major progress in the understanding of the pathophysiology and therapeutic options for common ageing-related musculoskeletal conditions (i.e. osteoporosis and associated fractures, sarcopenia and osteoarthritis), there is still a considerable proportion of patients who respond sub optimally to available treatments or experience adverse effects. Emerging microbiome research suggests that perturbations in microbial composition, functional and metabolic capacity (i.e. dysbiosis) are associated with intestinal and extra-intestinal disorders including musculoskeletal diseases. Besides its contributions to disease pathogenesis, the role of the microbiome is further extended to shaping individuals’ responses to disease therapeutics (i.e. pharmacomicrobiomics). In this review, we focus on the reciprocal interactions between the microbiome and therapeutics for osteoporosis, sarcopenia and osteoarthritis. Specifically, we identify the effects of therapeutics on microbiome’s configurations, functions and metabolic output, intestinal integrity and immune function, but also the effects of the microbiome on the metabolism of these therapeutics, which in turn, may influence their bioavailability, efficacy and side-effect profile contributing to variable treatment responses in clinical practice. We further discuss emerging strategies for microbiota manipulation as preventive or therapeutic (alone or complementary to available treatments) approaches for improving outcomes of musculoskeletal health and disease.

show abstract

Microbiota and Bone Health: The Gut-Musculoskeletal Axis

Cited by 9 publications

References 16 publications

A Combination of Celecoxib and Glucosamine Sulfate Has Anti-Inflammatory and Chondroprotective Effects: Results from an In Vitro Study on Human Osteoarthritic Chondrocytes

A Combination of Celecoxib and Glucosamine Sulfate Has Anti-Inflammatory and Chondroprotective Effects: Results from an In Vitro Study on Human Osteoarthritic Chondrocytes

Role of Dietary Supplements and Probiotics in Modulating Microbiota and Bone Health: The Gut-Bone Axis

Interactions of the microbiome with pharmacological and non-pharmacological approaches for the management of ageing-related musculoskeletal diseases

Contact Info

Product

Resources

About